In 2005, it was confirmed that the deletion of PD-1 by PD-1 deletion transgenic mice resulted in enhanced effector T-cell function and promoted the accumulation of cytotoxic T-cells at the tumor site [36]. This evidence concerns the gene PDCD1 and neoplasm.